News Column

Investigators at Murdoch Children's Research Institute Report Findings in DNA Vaccines (Effective pulmonary delivery of an aerosolized plasmid DNA...

July 17, 2014



Investigators at Murdoch Children's Research Institute Report Findings in DNA Vaccines (Effective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization)

By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Investigators discuss new findings in Biotechnology. According to news reporting from Parkville, Australia, by NewsRx journalists, research stated, "Pulmonary-delivered gene therapy promises to mitigate vaccine safety issues and reduce the need for needles and skilled personnel to use them. While plasmid DNA (pDNA) offers a rapid route to vaccine production without side effects or reliance on cold chain storage, its delivery to the lung has proved challenging."

The news correspondents obtained a quote from the research from Murdoch Children's Research Institute, "Conventional methods, including jet and ultrasonic nebulizers, fail to deliver large biomolecules like pDNA intact due to the shear and cavitational stresses present during nebulization. In vitro structural analysis followed by in vivo protein expression studies served in assessing the integrity of the pDNA subjected to surface acoustic wave (SAW) nebulisation. In vivo immunization trials were then carried out in rats using SAW nebulized pDNA (influenza A, human hemagglutinin H1N1) condensate delivered via intratracheal instillation. Finally, in vivo pulmonary vaccinations using pDNA for influenza was nebulized and delivered via a respirator to sheep. The SAW nebulizer was effective at generating pDNA aerosols with sizes optimal for deep lung delivery. Successful gene expression was observed in mouse lung epithelial cells, when SAW-nebulized pDNA was delivered to male Swiss mice via intratracheal instillation. Effective systemic and mucosal antibody responses were found in rats via post-nebulized, condensed fluid instillation. Significantly, we demonstrated the suitability of the SAW nebulizer to administer unprotected pDNA encoding an influenza A virus surface glycoprotein to respirated sheep via aerosolized inhalation."

According to the news reporters, the research concluded: "Given the difficulty of inducing functional antibody responses for DNA vaccination in large animals, we report here the first instance of successful aerosolized inhalation delivery of a pDNA vaccine in a large animal model relevant to human lung development, structure, physiology, and disease, using a novel, low-power (

For more information on this research see: Effective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization. Respiratory Research, 2014;15():1-12. Respiratory Research can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central - www.biomedcentral.com/; Respiratory Research - respiratory-research.com)

Our news journalists report that additional information may be obtained by contacting A.E. Rajapaksa, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia. Additional authors for this research include J.J. Ho, A. Qi, R. Bischof, T.H. Nguyen, M. Tate, D. Piedrafita, M.P. McIntosh, L.Y. Yeo, E. Meeusen, R.L. Coppel and J.R. Friend (see also Biotechnology).

Keywords for this news article include: Biotechnology, Parkville, Viral DNA, DNA Research, DNA Vaccines, Viral Vaccines, Influenza Vaccines, Synthetic Vaccines, Biological Products, Australia and New Zealand

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Gene Therapy Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters